JL18008
/ Jecho Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 07, 2026
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Jul 2027 ➔ Feb 2027
Enrollment open • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CXCL8 • IL4
June 06, 2026
A Study to Evaluate JL18008 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Jecho Biopharmaceuticals Co., Ltd.
New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CXCL8 • IL4
May 13, 2026
A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd.
New P1/2 trial • Human Immunodeficiency Virus • Infectious Disease • CD4 • CXCL8 • IL4
March 03, 2026
Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders
(clinicaltrials.gov)
- P1 | N=52 | Not yet recruiting | Sponsor: Jecho Biopharmaceuticals Co., Ltd.
New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4
1 to 4
Of
4
Go to page
1